NovaBay Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
SDEV$0.89-9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. FINANCIAL STATEMENTS
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value amounts)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,309 | $430 |
| Accounts receivable, net | 368 | — |
| Prepaid expenses and other current assets | 221 | 272 |
| Current assets, discontinued operations | — | 1,233 |
| Total current assets | 2,898 | 1,935 |
| Operating lease right-of-use assets | 189 | 955 |
| Property and equipment, net | 6 | 44 |
| Other assets | 394 | 480 |
| Other assets, discontinued operations | — | 9 |
| TOTAL ASSETS | $3,487 | $3,423 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Liabilities: | ||
| Current liabilities: | ||
| Accounts payable | $76 | $109 |
| Accrued liabilities | 807 | 581 |
| Bridge Loan | — | 500 |
| Unsecured Convertible Notes, net of discounts | 149 | 65 |
| Operating lease liabilities | 416 | 398 |
| Current liabilities, discontinued operations | — | 1,190 |
| Total current liabilities | 1,448 | 2,843 |
| Operating lease liabilities-non-current | 405 | 709 |
| Total liabilities | 1,853 | 3,552 |
| Commitments and contingencies (Note 7) | ||
| Mezzanine (temporary) equity: | ||
| Series F Preferred Stock; 1,987 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 525 | — |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.01 par value; 5,000 shares authorized; | ||
| Series B Preferred Stock; 1 shares issued and outstanding at each of September 30, 2025 and December 31, 2024 | 6 | 6 |
| Series D Preferred Stock; 481 and 0 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 3,786 | — |
| Common stock, $0.01 par value; 150,000 shares authorized, 6,011 and 4,885 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 60 | 49 |
| Additional paid-in capital | 181,074 | 183,273 |
| Accumulated deficit | (183,817) | (183,457) |
| Total stockholders’ equity (deficit) | 1,109 | (129) |
| TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) | $3,487 | $3,423 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.